

Basic Genomics closes a successful investment round led by Segulah Medical Acceleration and Navigare Ventures to Advance RNA Characterization Technologies

Stockholm, Sweden, 2025-04-25 – Basic Genomics, specializing in the characterization of RNA molecules, today announces the successful closing of a SEK 11.7 million investment round. The round was co-led by Segulah Medical Acceleration (SMA) and Navigare Ventures with strong support from existing shareholders.

The investment will support Basic Genomics in pioneering the characterization of RNA molecules to provide unique insights into human health and disease. The funds will be used to further develop the company's cutting-edge technologies, expand operational activities, and commercialization.

"We are happy to announce the successful closing of this funding round," said Gert-Jan Hendriks, CEO of Basic Genomics. "The strong interest and support we've received have been truly encouraging. With this investment, we are ready to enhance our product development and bring our innovative RNA research technologies to researchers more quickly."

SMA and Navigare Ventures, two Swedish based investors with a strong focus on early-/growth-stage science-driven companies, who together led the financing both have a strong confidence in Basic Genomics's potential to transform sequencing workflow of long RNA molecules.

"We are excited to co-lead the financing round for Basic Genomics, supporting a remarkable team dedicated to revolutionizing RNA research technologies. We envision great potential in strengthening these innovations to transform the research and development of new therapies and vaccines, among other applications.", said Karin Leire, Investment Director at SMA.

"The technology developed by Basic Genomics will unlock a new level of biological understanding by deciphering the transcriptional diversity that forms the basis of human health and disease. Backed by a team of top-tier researchers and entrepreneurs, their methodology will expand data modalities for new mechanistical insights, resonating well with one of our core investment themes." said Elin Almstedt, responsible for the investment at Navigare Ventures.

The advancements at Basic Genomics are expected to transform RNA analysis, making it more accurate, accessible and cost-effective for the global research community. This development is expected to have a profound impact on the field, paving way for the full potential of RNA research for a healthier future.

For further information about Basic Genomics, please contact Basic Genomics CEO at gert-jan.hendriks@basic-genomics.com.

About Basic Genomics

Basic Genomics is a deep tech spin-out from the Karolinska Institute, that develops innovative new methods to study RNA. The company's BaseCode technology platform enables unprecedented accuracy and throughput in the analysis of RNA isoforms, providing new insights into gene expression, cellular function and disease mechanisms.

Read more about Basic Genomics: www.basic-genomics.com

About Navigare Ventures

Navigare Ventures is an early-stage investment company specialized in science-driven companies. Navigare Ventures focus on deep tech, leveraging our expertise and network in areas such as AI, quantum technologies, data-driven life science, synthetic biology, and advanced materials. Based in Stockholm, Navigare Ventures is a wholly owned subsidiary of Wallenberg Investments AB. The investments drive long-term innovation and impact, while generating returns that help fund new academic research through the Wallenberg Foundations.

Read more about Navigare Ventures: www.navigareventures.com

About SMA

Segulah Medical Acceleration (SMA) is a Swedish investment company with an overarching philosophy of making investments that have a long-term, positive impact on people's health globally. The fund invests in and contributes to the development of leading companies in the life science sector, with a specific focus on medical devices, diagnostics, life science tools, and healthtech. SMA aims to support companies by providing capital, knowledge, experience, and access to industry networks. The goal is to help bridge the gap between innovation and commercial validation, bringing advanced research to global markets.

Read more about Segulah Medical Acceleration: www.segulahmedical.com